EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence of pathogenic variants in cancer‐predisposing genes in second cancer after childhood solid cancers

Masanori Yoshida iD, Kazuhiko Nakabayashi, Wentao Yang, Aiko Sato-Otsubo, Shin-Ichi Tsujimoto, Hiroko Ogata-Kawata, Tomoko Kawai, Keisuke Ishiwata, Mika Sakamoto, Kohji Okamura, Kaoru Yoshida, Ryota Shirai und 23 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.5835 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Masanori Yoshida und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology Research, Research Institute, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Neoplasms, Second Primary, Brain Neoplasms, Leukemia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Second malignant neoplasms (SMNs) are one of the most severe late complications after pediatric cancer treatment. However, the effect of genetic variation on SMNs remains unclear. In this study, we revealed germline genetic factors that contribute to the development of SMNs after treatment of pediatric solid tumors.

Methods

We performed whole‐exome sequencing in 14 pediatric patients with SMNs, including three brain tumors.

Results

Our analysis revealed that five of 14 (35.7%) patients had pathogenic germline variants in cancer‐predisposing genes (CPGs), which was significantly higher than in the control cohort ( p < 0.01). The identified genes with variants were TP53 ( n = 2), DICER1 ( n = 1), PMS2 ( n = 1), and PTCH1 ( n = 1). In terms of the type of subsequent cancer, leukemia and multiple episodes of SMN had an exceptionally high rate of CPG pathogenic variants. None of the patients with germline variants had a family history of SMN development. Mutational signature analysis showed that platinum drugs contributed to the development of SMN in three cases, which suggests the role of platinum agents in SMN development.

Conclusions

We highlight that overlapping effects of genetic background and primary cancer treatment contribute to the development of second cancers after treatment of pediatric solid tumors. A comprehensive analysis of germline and tumor samples may be useful to predict the risk of secondary cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasms, Second PrimaryBrain NeoplasmsLeukemiaChildHumansPrevalencePlatinumGerm-Line MutationGenetic Predisposition to DiseaseRibonuclease IIIDEAD-box RNA Helicases

Stichwörter der Autor:innen

cancer predispositionchildhood solid cancersecond malignant neoplasms

Substanzen

PlatinumDICER1 protein, humanRibonuclease IIIDEAD-box RNA Helicases

Autor:innen und Institutionen

  • Department of Pediatric Hematology and Oncology Research, Research Institute, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
  • Department of Maternal-Fetal Biology, Research Institute, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Tennessee, Memphis, USA.
  • Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Medical Genome Center, Research Institute, National Center for Child Health and Development, Tokyo, Japan.

ORCID-Profile: Masanori Yoshida, Masatoshi Takagi, Motohiro Kato

Förderung

  • NIGMS NIH HHS
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • National Center for Child Health and Development
  • National Institutes of Health

Zitieren

APA

Yoshida, M., Nakabayashi, K., Yang, W., Sato-Otsubo, A., Tsujimoto, S. I., Ogata-Kawata, H., Kawai, T., Ishiwata, K., Sakamoto, M., Okamura, K., Yoshida, K., Shirai, R., Osumi, T., Kiyotani, C., Shioda, Y., Terashima, K., Ishimaru, S., Yuza, Y., Takagi, M., …, & Kato, M. (2023). Prevalence of pathogenic variants in cancer‐predisposing genes in second cancer after childhood solid cancers. Cancer Medicine. https://doi.org/10.1002/cam4.5835

Vancouver

Yoshida M, Nakabayashi K, Yang W, Sato-Otsubo A, Tsujimoto SI, Ogata-Kawata H, et al. Prevalence of pathogenic variants in cancer‐predisposing genes in second cancer after childhood solid cancers. Cancer Medicine. 2023. doi:10.1002/cam4.5835

BibTeX
@article{Yoshida2023,
  author = {Yoshida, Masanori and Nakabayashi, Kazuhiko and Yang, Wentao and Sato-Otsubo, Aiko and Tsujimoto, Shin-Ichi and Ogata-Kawata, Hiroko and Kawai, Tomoko and Ishiwata, Keisuke and Sakamoto, Mika and Okamura, Kohji and Yoshida, Kaoru and Shirai, Ryota and Osumi, Tomoo and Kiyotani, Chikako and Shioda, Yoko and Terashima, Keita and Ishimaru, Sae and Yuza, Yuki and Takagi, Masatoshi and Arakawa, Yuki and Imamura, Toshihiko and Hasegawa, Daisuke and Inoue, Akiko and Yoshioka, Takako and Ito, Shuichi and Tomizawa, Daisuke and Koh, Katsuyoshi and Matsumoto, Kimikazu and Kiyokawa, Nobutaka and Ogawa, Seishi and Manabe, Atsushi and Niwa, Akira and Hata, Kenichiro and Yang, Jun J and Kato, Motohiro},
  title = {Prevalence of pathogenic variants in cancer‐predisposing genes in second cancer after childhood solid cancers},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5835}
}
Kostenlos starten →